| Document |
Document Title |
|
WO/2020/261886A1 |
An ultraviolet ray absorber represented by general formula (1) and a use therefor. In general formula (1), R11 represents a monovalent substituent group. n is 1 or 2. W1 and W2 each independently represent a hydrogen atom, a cyano group,...
|
|
WO/2020/227276A1 |
The disclosure provides thianthrene derivatized monomers and polymers for use in volume Bragg gratings, including, but not limited to, volume Bragg gratings for holography applications. Several thianthrene structures are described, inclu...
|
|
WO/2020/213693A1 |
The present disclosure provides a therapeutic or prophylactic agent for an ophthalmic disease such as presbyopia, said agent comprising, as an active ingredient, a lipoic acid prodrug having a specific structure.
|
|
WO/2020/187155A1 |
Use of an apocynin dimer analogue derivative in preparing a medicament or a health care product for preventing and treating Parkinson's disease. The structure of the apocynin dimer analogue derivative is as shown in formula I. The apocyn...
|
|
WO/2020/121823A1 |
The present invention addresses the problem of providing: a liquid crystal composition which is to be used in an active drive display element and improves chromatic dispersion properties; a display element which uses said liquid crystal ...
|
|
WO/2020/109148A1 |
A photoinitiator selected from the group consisting of an acylphosphine oxide, a α-hydroxy-ketone and a α-amino-ketone, characterized in that the photoinitiator includes at least one aliphatic disulfide as functional group.
|
|
WO/2020/106028A1 |
The present specification provides a compound represented by chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2020/094673A1 |
Thianthrene derivative of the Formula (I): wherein R1 to R8 may be the same or different and are selected from hydrogen, Cl, F, a partially or fully fluorinated C1 to C6 alkyl group, and wherein n is 0 or 1, with the proviso that at leas...
|
|
WO/2020/078369A1 |
Provided are a phenolic derivative, preparation method therefor and use thereof. The phenolic derivative has a structure as shown in formula (I), and the definitions of the groups therein are shown in the description. The phenolic deriva...
|
|
WO/2020/041871A1 |
This application is directed to the use of a ketogenic agent, such as 1,3-butanediol, R-β-hydroxybutyl-R-β-hydroxybutyrate, or triheptanoin, in the treatment of an individual having a lysosomal storage disease, including Pompe disease....
|
|
WO/2020/035826A1 |
The present invention discloses 1,2-dithiolone compounds of the formula (I), wherein, A, Cy, R, R1, R2a and R2b have the same meanings as defined in the description. The present invention further discloses methods for their preparation a...
|
|
WO/2019/241644A8 |
The invention relates to methods of treating cell proliferative disorders. The invention further relates to pharmaceutical compositions for treating cell proliferative disorders, especially cancer.
|
|
WO/2019/241644A1 |
The invention relates to methods of treating cell proliferative disorders. The invention further relates to pharmaceutical compositions for treating cell proliferative disorders, especially cancer.
|
|
WO/2019/227202A1 |
Disclosed are pharmaceutical salts and co-crystals of pentoxifylline, clonidine and linsidomine with caffeic acid, protocatechuic acid or α-lipoic acid, and method for preparing thereof. Also disclosed are topical compositions comprisin...
|
|
WO/2019/178689A1 |
A method for promoting weight management in a mammal is provided, comprising administering to the mammal a composition comprising at least one weight loss agent and at least one mitochondria enhancing agent. The weight loss agent may be ...
|
|
WO/2019/161280A1 |
The present disclosure relates to methods and intermediates useful for preparing a compound of formula (I): (I) or a co-crystal, solvate, salt or combination thereof.
|
|
WO/2019/150341A1 |
The present disclosure relates to pharmaceutical compositions comprising a therapeutically effective amount of an antimuscarinic or an anticholinergic agent or a pharmaceutically acceptable salt or a stereoisomer thereof in combination w...
|
|
WO/2019/149091A1 |
The present invention relates to the field of compounds, and in particular to a probucol derivative, a preparation method therefor and use thereof, the probucol derivative having a structure represented by general formula I. The probucol...
|
|
WO/2019/142539A1 |
A composition comprising a compound represented by formula (I) and a compound represented by formula (III); a curable composition; and a compound. R11 represents an unsubstituted alkyl group. R12, R13, R32, and R33 each independently rep...
|
|
WO/2019/129403A1 |
The present invention concerns the field of neurodegenerative diseases, and in particular relates to compounds, pharmaceutical compositions and their uses in the protection of neuronal cells from inflammation and from oxidative stress in...
|
|
WO/2019/124154A1 |
Provided are: a polymerizable liquid-crystal compound suitable for producing positive-C-plate retarder films which have excellent heat resistance and reverse wavelength dispersion characteristics; a polymerizable liquid-crystal compositi...
|
|
WO/2019/111853A1 |
The present invention addresses the problem of providing a method for producing a dicarboxylic acid monoester with excellent production efficiency, a method for producing a polymerizable liquid crystal compound, and a novel dicarboxylic ...
|
|
WO/2019/108033A1 |
The present specification provides a compound represented by chemical formula 1, and an organic light emitting element comprising the same.
|
|
WO/2019/087054A1 |
The present invention relates to novel pharmaceutical composition comprising DPP-4 inhibitor, Alpha-lipoic acid and Vitamin B12. The synergism of DPP-4 inhibitor, Alpha- lipoic acid and Vitamin B12 helps in the treatment of diabetes and ...
|
|
WO/2019/071353A1 |
A method of reducing glutamate efflux from skeletal muscle by inhibiting system Xc- activity is provided. The method is useful for the treatment of statin-induced myalgia. Pharmaceutical compositions useful to treat statin-induced myalgi...
|
|
WO/2019/061299A1 |
Provided is a one-step amination reaction for producing an aminomethyl substituted heterocycloalkane, notably (tetrahydrofuran-2, 5-diyl) dimethanamine.
|
|
WO/2019/065043A1 |
Provided are a compound production method capable of producing a benzothiol compound having little coloration, a composition, and a curable composition. The method is for producing a compound represented by formula (1) and comprises reac...
|
|
WO/2019/044863A1 |
The present invention provides a cured product which is obtained by curing a curable composition that contains a compound represented by general formula 1, and which has a birefringence ∆n (587 nm) satisfying 0.00 ≤ ∆n (587 nm) ≤...
|
|
WO/2019/017445A1 |
The present invention addresses the problem of providing: a polymerizable liquid crystal compound which is used in formation of an optically anisotropic membrane having excellent reverse wavelength dispersibility; a polymerizable liquid ...
|
|
WO/2019/017444A1 |
The present invention addresses the problem of providing: a polymerizable liquid crystal compound which is used in formation of an optically anisotropic membrane having excellent reverse wavelength dispersibility and excellent moist heat...
|
|
WO/2018/167677A1 |
An object of the present invention is to provide a dithiolane compound or a salt or an N-oxide thereof that controls diseases. The present invention provides a dithiolane compound represented by Formula (1) or a salt or an N-oxide thereo...
|
|
WO/2018/155498A1 |
The present invention addresses the problem of providing a polymerizable liquid crystal compound that exhibits superior solubility and is used to form an optically anisotropic film exhibiting superior durability, and a method of producin...
|
|
WO/2018/128800A1 |
The disclosure is directed to compounds of formula (I). Methods of using these compounds, particularly as antimicrobial agents, are also described
|
|
WO/2018/119526A1 |
The invention relates to a natural biostimulant composition for improving agricultural production, specifically to a biostimulant composition for plants which contains lipoic acid and which is unknown in the prior art, and to a method fo...
|
|
WO/2018/101207A1 |
The present invention addresses the problem of providing: a polymerizable liquid crystal composition that makes it possible to manufacture an optical film that has excellent light resistance; and an optically anisotropic membrane, an opt...
|
|
WO/2018/049127A1 |
This invention provides confounds of the formula (I): wherein Y1, Y2 Z, X1, X2, and W are defined in the specification. These compounds are useful in the treatment of tyrosine kinases, MAPK signaling pathway kinases and Ρ13K/ΑΚΤ/mTor...
|
|
WO/2018/041935A1 |
The present invention relates to photoinitiator compounds of the formula (1) wherein X is O, S or a direct bond; Y is O, S or CR9R10; R1, R2, R3, R4, R5, R6, R7 and R8 independently of each other are hydrogen, halogen, C1- C18alkyl, C5-C...
|
|
WO/2018/033493A1 |
The present invention relates to liquid aromatic thioethers, a process for the preparation of the liquid aromatic thioethers, an article comprising the liquid aromatic thioethers as well as the use of the liquid aromatic thioethers as a ...
|
|
WO/2018/024901A1 |
The present invention relates to the use of a thianthrene-containing polymer as a redox-active electrode material, for example in the form of an electrode slurry, for electrical charge stores, in particular secondary batteries. The inven...
|
|
WO/2018/020974A1 |
Provided are the following: a sulfonium salt which does not contain a toxic metal and which exhibits higher cationic polymerization performance and crosslinking performance than a tetrakis(pentafluorophenyl)borate salt; a heat- or photo-...
|
|
WO/2018/014408A1 |
Provided are a light-emitting material, a preparation method therefor and an organic light-emitting diode using said light-emitting material. The light-emitting material has a single structure, a definite molecular weight, a better solub...
|
|
WO/2018/012762A1 |
The present invention relates to a novel compound and an organic electroluminescent device comprising same. The compound, according to the present invention, can be used in an organic layer, preferably a light-emitting layer, of an organ...
|
|
WO/2017/202266A1 |
The present invention relates to a 2-amino-3-substituted mercaptopropionate derivative, a preparation method therefor and a use thereof. The 2-amino-3-substituted mercaptopropionate derivative according to the present invention has a str...
|
|
WO/2017/181004A1 |
The disclosure of a compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) The variables W, R1, R2, R3, and R4 are defined in the disclosure. The disclosure provides a compound or salt of Formula (I) together with a ph...
|
|
WO/2017/085733A3 |
The disclosure herein provides certain analgesic 2,6-xylidine derivatives or its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof. These compounds may be formulated as pharmaceutical compositions for...
|
|
WO/2017/098988A1 |
The present invention provides a polymerizable liquid crystal compound that is highly soluble in various kinds of solvent and that has reverse-wavelength dispersibility or low-wavelength dispersibility. The present invention also provide...
|
|
WO/2017/093558A1 |
The invention relates to the dyeing of keratin materials using anionic direct dyes containing a disulfide heterocyclic group. The invention relates to a dye composition comprising a fluorescent dye containing a disulfide heterocyclic gro...
|
|
WO/2017/085733A2 |
The disclosure herein provides a composition of compound of formula 1. The disclosure also provides a method of synthesizing the compound of formula 1 and its improved processes. The compound of formula 1 or its pharmaceutical acceptable...
|
|
WO/2017/060914A3 |
Penicillamine and its derivatives, composition, methods of synthesizing and using the compound of formula 1 are disclosed. The compounds of formula 1 also comprises of salts, polymorphs, solvates and hydrates thereof. The compounds may b...
|
|
WO/2017/078927A1 |
Novel compounds having a formula (I), embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a s...
|
